Divergence in Perceptions of Diabetes Control among Patients with T2DM and Health Care Professionals (HCPs)

Background: Sixty percent of patients with T2DM on basal insulin have an A1C ≥7%. This study aimed to understand patient and HCP views of “control,” as this may impact how many patients reach an A1C Methods: A cross-sectional, web-based survey of 500 HCPs (primary care physicians, endocrinologists, nurse practitioners/physician assistants) and 618 adults with T2DM using basal insulin was conducted to assess perceptions, attitudes and behaviors associated with T2DM management. The survey was developed based on feedback from focus groups and piloted. Patients self-reported A1C and were asked to confirm the value with their HCP, if necessary. Results: Patients and HCPs differed on what it meant to be “in control.” A1C was used most often, but more frequently selected by HCPs (91% vs. 69%), followed by daily blood glucose meter readings (63% HCPs vs. 68% patients). Beyond A1C and daily blood glucose, patients most frequently used behavioral criteria (e.g., adherence to lifestyle changes and/or treatment regimens); HCPs most frequently used clinical criteria (e.g., hypoglycemia). The timeframe for defining control varied among patients, with those at A1C>8% more frequently reporting “the current moment” or “the past week.” Most HCPs focused on the last 3 months to define control (67% vs. 34% all patients, p Conclusions:Patients with T2D in the U.S. have differing views from HCPs on key aspects of diabetes control and management, and are less likely to consider A1C value as a criterion for determining control. Recognizing these differences may improve communication, with the potential to improve patient outcomes. Disclosure M. Brod: Consultant; Self; Novo Nordisk A/S. K.J. Tomaszewski: Research Support; Self; Novo Nordisk Inc. A. Allen: Research Support; Self; Novo Nordisk Inc. D.F. Kruger: Research Support; Self; Dexcom, Inc.. Speaker9s Bureau; Self; Dexcom, Inc.. Stock/Shareholder; Self; Dexcom, Inc.. Consultant; Self; Novo Nordisk Inc.. Speaker9s Bureau; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc.. Speaker9s Bureau; Self; Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc.. Consultant; Self; Intarcia Therapeutics, Inc., Abbott. Research Support; Self; Sanofi. Consultant; Self; Sanofi. Research Support; Self; JAEB Center For Health Research. Consultant; Self; Janssen Pharmaceuticals, Inc.. Speaker9s Bureau; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; AstraZeneca. Speaker9s Bureau; Self; AstraZeneca. Research Support; Self; Hygieia, Lexicon Pharmaceuticals, Inc., National Institute of Diabetes and Digestive and Kidney Diseases. Speaker9s Bureau; Self; Valeritas, Inc., Insulet Corporation. Consultant; Self; Insulet Corporation. Research Support; Self; Insulet Corporation. Consultant; Self; Merck & Co., Inc. M.K. Heile: Advisory Panel; Self; Novo Nordisk Inc.. Speaker9s Bureau; Self; Novo Nordisk Inc., Insulet Corporation. Advisory Panel; Self; Dexcom, Inc.. Speaker9s Bureau; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Roche Diagnostics Corporation. M. Mocarski: Employee; Self; Novo Nordisk Inc.. Stock/Shareholder; Self; Novo Nordisk A/S. A. Schiffman: Employee; Self; Novo Nordisk Inc. Y. Handelsman: Consultant; Self; Amarin Corporation. Speaker9s Bureau; Self; Amarin Corporation. Board Member; Self; American Association of Clinical Endocrinologists. Consultant; Self; Amgen Inc.. Research Support; Self; Amgen Inc.. Speaker9s Bureau; Self; Amgen Inc.. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. Speaker9s Bureau; Self; AstraZeneca. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Gan & Lee Pharmaceuticals. Consultant; Self; Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc.. Speaker9s Bureau; Self; Janssen Pharmaceuticals, Inc.. Research Support; Self; Lexicon Pharmaceuticals, Inc.. Consultant; Self; Merck & Co., Inc.. Research Support; Self; Merck & Co., Inc.. Consultant; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc.. Speaker9s Bureau; Self; Novo Nordisk Inc., Regeneron Pharmaceuticals, Inc.. Consultant; Self; Sanofi. Research Support; Self; Sanofi. Speaker9s Bureau; Self; Sanofi.